Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1

Conditions

Ovarian Neoplasms 3Prostatic Neoplasms 1Peripheral Nervous System Diseases 1

Interventions

pembrolizumab 14Specimen Handling 8Docetaxel 8olaparib 7Nivolumab 7Gemcitabine 7Trastuzumab 6Paclitaxel 6rucaparib 5Magnetic Resonance Spectroscopy 5Early Intervention, Educational 5Biopsy 5Standard of Care 4Cyclophosphamide 4Carboplatin 4tisotumab vedotin 3talazoparib 3pertuzumab 3durvalumab 3atezolizumab 3Taxes 3Surveys and Questionnaires 3Sirolimus 3Radiotherapy 3Psychiatric Rehabilitation 3Methods 3Irinotecan 3Immunoglobulin G 3Fulvestrant 3Educational Status 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × sagopilone × Gynecologic × Clear all
NCT00751205 2014-10-28

Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Bayer

Phase 2 Completed
150 enrolled
GenitourinaryGynecologic

Ovarian Neoplasms, Peripheral Nervous System Diseases, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡